Nyxoah S.A., a Mont-Saint-Guibert, Belgium – based healthtech company developing neuromodulation-based therapeutic solutions for sleep disordered breathing conditions, raised €25m in financing.
The completion of the round is subject to customary closing conditions and is expected to occur later this month. ResMed Inc. (NYSE:RMD) (ASX:RMD), a digital health company in the fields of sleep apnea, COPD, and other chronic diseases, joined as a new shareholder. Under the lead of Mr. Robert Taub, Nyxoah executive chairman, Cochlear Limited (ASX:COH) and several historical shareholders completed the round.
The proceeds will enable the company to further advance in developing long-term clinical evidence on the Genio® system, prepare for the IDE pivotal trial in the United States and accelerate the ongoing market access and commercialisation activities in Europe, Australia and New Zealand.
Led by Olivier Taelman, CEO, Nyxoah is a healthtech company focused on the development and commercialisation of innovative solutions and services for sleep disordered breathing conditions. Its lead solution platform is based on the Genio® system, a validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA. The Genio® system received its European CE Mark in March 2019.
The company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system. The IDE pivotal study to prepare for US market entrance is currently in discussion with the FDA.